Related references
Note: Only part of the references are listed.Combined effect of fluconazole and thymosin α1 on systemic candidiasis in mice immunosuppressed by morphine treatments
P. FRANCESCO et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma
E. -K. Song et al.
ANNALS OF ONCOLOGY (2008)
Immunogenic anti-cancer chemotherapy as an emerging concept
Nicole M. Haynes et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: A report from the 11715 study group
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma
A. Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study
O. Hamid et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
Edward L. Korn et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Immunotherapy for Advanced Melanoma
Lei Fang et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
A. M. Krieg
ONCOGENE (2008)
Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients
Wei Zhou et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group
Agop Y. Bedikian et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma:: a randomized phase III trial of the DC study group of the DeCOG
D Schadendorf et al.
ANNALS OF ONCOLOGY (2006)
Chemotherapy and targeted therapy combinations in advanced melanoma
KT Flaherty
CLINICAL CANCER RESEARCH (2006)
Cranking the immunologic engine with chemotherapy: Using context to drive tumor antigen cross-presentation towards useful antitumor immunity
RG van der Most et al.
CANCER RESEARCH (2006)
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: A randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group
U Keilholz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma:: A phase III study
MF Avril et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cancer immunotherapy: moving beyond current vaccines
SA Rosenberg et al.
NATURE MEDICINE (2004)
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
AMM Eggermont et al.
EUROPEAN JOURNAL OF CANCER (2004)
Thymosin α 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling
L Romani et al.
BLOOD (2004)
Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells
AK Nowak et al.
JOURNAL OF IMMUNOLOGY (2003)
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial
O Eton et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system
CM Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma:: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)
A Hauschild et al.
BRITISH JOURNAL OF CANCER (2001)
Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients
VC Sileni et al.
MELANOMA RESEARCH (2001)
Combined treatment with thymosin-α1 and low dose interferon-α after dacarbazine in advanced melanoma
G Rasi et al.
MELANOMA RESEARCH (2000)
Share Paper
